Ann: BTX 1801 Kills Superbugs Without Resistance World-First, page-457

First 457 Last

Share
Profile

Follow
procrastinator

931 Posts.

111

21/06/19

16:35

Post #: 39179161
Share

Originally posted by bernsta ↑

So managed to have a nice conversation with Matt this afternoon - i scribbled down what I could, brief update below whilst some is fresh in my head and in front of me:

My questions and key takeaways:

Q) If BTX1801 works on animal wounds, would we expect it work on humans ?

A) Does not foresee any issues at all as the models are translated into human efficacy and the bugs are done in real life situations with the anti-microbal effect. Essentially the Phase 1 and 1B studies are already completed here as they are replicating the studies with AD and Acne. The bacteria forms no resistance. Indicated that they somewhat stumbled upon this little beauty and thinks this may actually be bigger then other products in terms of value. Mentioned a huge market cap alone for this product when compared to NXS valuation.

Q) Are we looking at a CR?

A) He could not have said NO any clearer - he said many brokers have approached him regarding this basically seeking a 20% placement and he's told them to buy on marke (and he admitted they needed the cash back then). With the R & D rebate and the cash on hand to come they are fully funded to phase 2 trials. He said he will let the results decide the price. He feels this put a strangle on the share price in the past, which is why it hasn't run as much as it should have. He wants the price to run and the data to do the talking.

Q) How did Vince come over?

A) He did a good 6-12 months due diligence prior - BOT did approach him, but scoring him is a huge bonus for the company. 12 months ago big pharma had no idea on CBD. BOT essentially has a 3 year head start on anyone in this space.

Q) Trials for phase 2 studies running on time ?

A) No issues with timing, all running on time and as expected, results expected to be released next quarter as mentioned. Going very well as planned.

Q) Are big pharma sniffing?

A) Has had many meetings with big pharma already. They all ask the same q'n - how do you do what you do? He laughs in response. Will let data do the talking. He plans to be back in 6-8 weeks and regularly come to Aus from now on.

There is more - but wanted to provide a brief update on key issues - he's obviously having a very big day with meetings. Was very nice of him to give me half an hour.

This company is extremely easy to get in contact with. Matt is extremely accommodating and I encourage holders to get in touch.

Have a fantastic weekend.

Expand

The clarification around a CR is great news. Nice to hear that he is going to let the share price run, its about time he did.
Really well done @bernsta, thanks heaps for sharing with community.

BOT Price at posting: 18.0¢ Sentiment: Buy Disclosure: Held
16 Upvote

0 Great analysis

Reply

Top Stories

KAR

Karoon up nearly 8% on strong 4th quarter results, record 2024 revenue

WIN

Out to WIN: The 'primed' gold play with sights set on WA production

BM8

Battery Age Minerals finds critical technology isotope Germanium-76 at Bleiberg

DeepSeek is living in the market's head rent-free. But it's not China's only breakthrough of 2025

CC9

Is a lithium revival on the cards in 2025? Chariot Corporation say yes!

First 457 Last

Add BOT (ASX) to my watchlist

(20min delay)
Last 43.5¢		Change 0.000(0.00%)		Mkt cap ! $794.1M

Open	High	Low	Value	Volume
43.5¢	44.5¢	43.0¢	$2.324M	5.314M

Buyers (Bids)

No.	Vol.	Price($)
11	391693	43.0¢

Sellers (Offers)

Price($)	Vol.	No.
43.5¢	80106	3

View Market Depth

No.	Vol.	Price($)
11	391693	0.430
11	159884	0.425
10	74408	0.420
8	218257	0.415
13	143409	0.410

Price($)	Vol.	No.
0.435	80106	3
0.440	795	1
0.445	120000	1
0.450	224064	7
0.455	180485	6

Last trade - 16.10pm 30/01/2025 (20 minute delay)

BOT (ASX) Chart

Ann: BTX 1801 Kills Superbugs Without Resistance World-First, page-457

Karoon up nearly 8% on strong 4th quarter results, record 2024 revenue

Out to WIN: The 'primed' gold play with sights set on WA production

Battery Age Minerals finds critical technology isotope Germanium-76 at Bleiberg

DeepSeek is living in the market's head rent-free. But it's not China's only breakthrough of 2025

Is a lithium revival on the cards in 2025? Chariot Corporation say yes!

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: BTX 1801 Kills Superbugs Without Resistance World-First, page-457

Top Stories

Karoon up nearly 8% on strong 4th quarter results, record 2024 revenue

Out to WIN: The 'primed' gold play with sights set on WA production

Battery Age Minerals finds critical technology isotope Germanium-76 at Bleiberg

DeepSeek is living in the market's head rent-free. But it's not China's only breakthrough of 2025

Is a lithium revival on the cards in 2025? Chariot Corporation say yes!

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News